Table 1 Clinical trials on the bi-inhibition of TIGIT and PD-1/PD-L1 registered on clinicaltrials.gov

1

NCT04948697

2

Active, not recruiting

Advanced Liver Cancers

Ociperlimab plus Tislelizumab plus BAT1706

Tislelizumab plus BAT1706

-

2

NCT05724563

2

Not yet recruiting

Advanced Liver Cancers

Zimberelimab plus Domvanalimab

-

-

3

NCT04524871

1/2

Recruiting

Advanced Liver Cancers

Atezolizumab plus Bevacizumab plus Tiragolumab

Atezolizumab plus Bevacizumab

Atezolizumab plus Bevacizumab plus Tocilizumab

Atezolizumab plus Bevacizumab plus TPST-1120

RO7247669 plus Bevacizumab

Atezolizumab plus Bevacizumab plus ADG126

-

4

NCT04911894

1

Completed

Advanced Solid Tumor

IBI321

-

-

5

NCT04911881

1

Completed

Advanced Solid Tumor

IBI321

-

-

6

NCT02913313

1/2

Active, not recruiting

Advanced Solid Tumor

BMS-986,207 plus nivolumab

BMS-986,207 plus nivolumab plus ipilimumab

BMS-986,207

-

-

7

NCT02794571

2

Active, not recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

-

ORR_dual: 46% (6/13)

DCR_dual: 85% (11/13)

8

NCT02964013

1

Active, not recruiting

Advanced Solid Tumor

Vibostolimab plus pembrolizumab

Vibostolimab plus pembrolizumab plus chemotherapy

MK-7684 A

Vibostolimab plus chemotherapy

Vibostolimab

-

ORR_dual: 26%

mPFS_dual: 8.4 months

9

NCT04570839

1/2

Active, not recruiting

Advanced Solid Tumor

COM701 plus BMS-986,207 plus Nivolumab

-

ORR_dual: 20% (4/20)

DCR_dual: 45% (9/20)

10

NCT03628677

1

Active, not recruiting

Advanced Solid Tumor

Domvanalimab plus Zimberelimab

Domvanalimab

-

-

11

NCT04457778

1

Active, not recruiting

Advanced Solid Tumor

M6223 plus Bintrafusp alfa

M6223

-

-

12

NCT04632992

2

Active, not recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

Entrectinib

Inavolisib

Alectinib

Ipatasertib

Atezolizumab plus Investigator’s Choice of Chemotherapy

Trastuzumab Emtansine plus Atezolizumab

Pertuzumab plus Trastuzumab plus Hyaluronidase-zzxf

Pertuzumab plus Trastuzumab plus Hyaluronidase-zzxf plus Investigator’s Choice of Chemotherapy

Trastuzumab Emtansine plus Tucatinib

Trastuzumab Emtansine plus Atezolizumab

Ipatasertib plus Atezolizumab

Ipatasertib plus Paclitaxel

Pralsetinib

-

13

NCT03260322

1

Completed

Advanced Solid Tumor

ASP8374 plus Pembrolizumab

ASP8374

-

-

14

NCT04353830

1

Completed

Advanced Solid Tumor

IBI939 plus Sintilimab

IBI939

-

-

15

NCT04335253

1

Completed

Advanced Solid Tumor

EOS-448

-

-

16

NCT03945253

1

Completed

Advanced Solid Tumor

ASP8374

-

-

17

NCT05172856

1

Not yet recruiting

Advanced Solid Tumor

IBI321

-

-

18

NCT05483400

2

Not yet recruiting

Advanced Solid Tumor

Tiragolumab plus Atezolizumab

-

-

19

NCT05259319

1

Not yet recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab plus SBRT

-

-

20

NCT05537051

1

Not yet recruiting

Advanced Solid Tumor

PM1021 plus PM8001

PM1021

-

-

21

NCT05715281

2

Not yet recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

-

-

22

NCT05661578

2

Recruiting

Advanced Solid Tumor

Tiragolumab plus Atezolizumab

-

-

23

NCT05286801

1/2

Recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

-

-

24

NCT03977467

2

Recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

Atezolizumab plus chemotherapy

-

25

NCT04047862

1

Recruiting

Advanced Solid Tumor

Ociperlimab plus Tislelizumab

Ociperlimab plus Tislelizumab plus chemotherapy

Ociperlimab

-

ORR_dual: 57.5% vs. ORR_dual+C: 54.8%

26

NCT05417321

1/2

Recruiting

Advanced Solid Tumor

HB0036

-

-

27

NCT05026606

2

Recruiting

Advanced Solid Tumor

Etigilimab plus Nivolumab

-

-

28

NCT04761198

1/2

Recruiting

Advanced Solid Tumor

Etigilimab plus Nivolumab

-

-

29

NCT04354246

1

Recruiting

Advanced Solid Tumor

COM902 plus COM701 plus Pembrolizumab

COM902 plus COM701

COM902

-

-

30

NCT05120375

1

Recruiting

Advanced Solid Tumor

BAT6021

-

-

31

NCT05073484

1

Recruiting

Advanced Solid Tumor

BAT6021 plus BAT1308

BAT6021

-

-

32

NCT05060432

1/2

Recruiting

Advanced Solid Tumor

EOS-448 plus Pembrolizumab

EOS-448 plus Inupadenant

EOS-448 plus Dostarlimab

EOS-448 plus Dostarlimab plus Inupadenant

EOS-448 plus Dostarlimab plus chemotherapy

Inupadenant plus Dostarlimab

-

33

NCT05007106

2

Recruiting

Advanced Solid Tumor

MK-7684 A

MK-7684 A plus Lenvatinib

MK-7684 A plus 5-Fluorouracil plus Cisplatin

MK-7684 A plus Paclitaxel

MK-7684 A plus Gemcitabine/Cisplatin

MK-7684 A plus Carboplatin/Paclitaxel/Bevacizumab

MK-7684 A plus Capecitabine/Oxaliplatin

Pembrolizumab

-

34

NCT04446351

1

Recruiting

Advanced Solid Tumor

EOS-448 plus Dostarlimab

EOS-448 plus Dostarlimab plus GSK6097608

GSK6097608

GSK6097608 plus Dostarlimab

Dostarlimab

Dostarlimab plus Cobolimab

-

35

NCT03869190

1/2

Recruiting

Advanced Solid Tumor

Atezolizumab plus Tiragolumab

Atezolizumab

Atezolizumab plus Enfortumab Vedotin

Atezolizumab plus Niraparib

Atezolizumab plus Magrolimab

Atezolizumab plus Sacituzumab Govitecan

Atezolizumab plus RO7122290

Cisplatin

-

36

NCT05757492

1/2

Recruiting

Advanced Solid Tumor

JS006 plus Toripalimab

-

-

37

NCT05394337

1

Not yet recruiting

Advanced Urothelial Carcinoma

Neoadjuvant atezolizumab plus Tiragolumab

-

-

38

NCT05845814

1/2

Not yet recruiting

Advanced Urothelial Carcinoma

MK-7684 A plus EV

Coformulated Favezelimab/Pembrolizumab plus EV

Pembrolizumab plus EV

-

39

NCT05327530

2

Recruiting

Advanced Urothelial Carcinoma

Avelumab plus M6223

Avelumab

Avelumab plus Sacituzumab Govitecan

Avelumab plus NKTR-255

-

40

NCT03547973

2

Recruiting

Advanced Urothelial Carcinoma

Sacituzumab Govitecan-hziy plus Zimberelimab plus Domvanalimab

Sacituzumab Govitecan-hziy

Sacituzumab Govitecan-hziy plus Pembrolizumab

Sacituzumab Govitecan-hziy plus Cisplatin plus Avelumab

Sacituzumab Govitecan-hziy plus Cisplatin plus Zimberelimab

Sacituzumab Govitecan-hziy plus Zimberelimab

Avelumab

Zimberelimab

Carboplatin plus Gemcitabine

-

41

NCT05645692

2

Recruiting

Advanced Urothelial Carcinoma

Tiragolumab plus R07247669

RO7247669

Atezolizumab

-

42

NCT05023109

2

Recruiting

Biliary Tract Carcinoma

Tislelizumab plus Ociperlimab plus chemotherapy

-

-

43

NCT02625961

2

Recruiting

Bladder Cancer

MK-7684 A

Pembrolizumab

-

44

NCT04693234

2

Active, not recruiting

Cervical Cancer

Tislelizumab plus Ociperlimab

Tislelizumab

-

45

NCT04300647

2

Active, not recruiting

Cervical Cancer

Tiragolumab plus Atezolizumab

Atezolizumab

-

46

NCT04895722

2

Recruiting

Colorectal Cancer

MK-7684 A

Pembrolizumab

Co-formulated Pembrolizumab/Quavonlimab

Co-formulated Pembrolizumab/Favezelimab

Pembrolizumab Plus MK-4830

-

47

NCT04929223

1

Recruiting

Colorectal Cancer

Atezolizumab plus Tiragolumab plus Bevacizumab

Atezolizumab plus Tiragolumab

Inavolisib plus Cetuximab

Inavolisib plus Bevacizumab

Atezolizumab plus SY-5609

GDC-6036 plus Cetuximab plus FOLFOX

GDC-6036 plus Cetuximab

-

48

NCT04486352

1/2

Recruiting

Endometrial Cancer

Atezolizumab plus Tiragolumab

Atezolizumab plus Bevacizumab

Atezolizumab plus Ipatasertib

Atezolizumab plus Talazoparib

Atezolizumab plus Trastuzumab emtansine (TDM-1)

Inavolisib plus Letrozole

-

49

NCT04540211

3

Active, not recruiting

ESCC

Tiragolumab plus Atezolizumab plus chemotherapy

Placebo plus chemotherapy

-

50

NCT05743504

1/2

Not yet recruiting

ESCC

Tiragolumab plus Atezolizumab with CCRT before surgery

-

-

51

NCT04732494

2

Recruiting

ESCC

Tislelizumab plus Ociperlimab

Tislelizumab plus Placebo

-

52

NCT04543617

3

Recruiting

ESCC

Tiragolumab plus Atezolizumab

Tiragolumab

Atezolizumab plus Placebo

-

53

NCT03281369

1/2

Recruiting

ESCC

Atezolizumab plus Tiragolumab plus chemotherapy

Atezolizumab plus Tiragolumab

Atezolizumab

-

54

NCT04933227

2

Active, not recruiting

Gastric Cancer

Tiragolumab plus Atezolizumab plus chemotherapy

-

-

55

NCT05251948

1/2

Active, not recruiting

Gastric Cancer

Tiragolumab plus Atezolizumab plus chemotherapy

Atezolizumab plus chemotherapy

-

56

NCT05568095

3

Recruiting

Gastric Cancer

Zimberelimab plus Domvanalimab plus chemotherapy

Nivolumab plus chemotherapy

-

57

NCT05329766

2

Recruiting

Gastric Cancer

Domvanalimab plus Zimberelimab plus chemotherapy

Domvanalimab plus Zimberelimab

Zimberelimab plus chemotherapy

Zimberelimab plus Quemliclustat

-

58

NCT05702229

2

Recruiting

Gastric Cancer

AZD2936 Plus XELOX/FOLFOX

MEDI5752 plus XELOX/FOLFOX

-

59

NCT04826393

1

Active, not recruiting

Glioblastoma

ASP8374 plus Cemiplimab

-

-

60

NCT04656535

1

Recruiting

Glioblastoma

AB122 plus Domvanalimab plus surgery

AB122 plus Domvanalimab

Domvanalimab plus surgery

AB122 plus surgery

surgery

-

61

NCT05130177

2

Recruiting

Melanoma

Zimberelimab plus Domvanalimab

-

-

62

NCT05665595

3

Recruiting

Melanoma

Pembrolizumab plus Vibostolimab

Pembrolizumab

-

63

NCT05060003

2

Recruiting

Melanoma

Atezolizumab plus Tiragolumab

Atezolizumab

-

64

NCT04305041

1/2

Recruiting

Melanoma

Pembrolizumab plus Quavonlimab plus Vibostolimab

Pembrolizumab plus Quavonlimab plus Lenvatinib

Pembrolizumab plus all-trans retinoic acid (ATRA)

-

65

NCT04305054

1/2

Recruiting

Melanoma

Pembrolizumab plus Vibostolimab

Coformulation Favezelimab/Pembrolizumab plus Vibostolimab

Pembrolizumab

Coformulation Pembrolizumab/Quavonlimab

Coformulation Pembrolizumab/Quavonlimab plus Lenvatinib

Coformulation Favezelimab/Pembrolizumab

Coformulation Favezelimab/Pembrolizumab plus All-trans Retinoic Acid (ATRA)

-

66

NCT04303169

1/2

Recruiting

Melanoma

Pembrolizumab plus Vibostolimab

Pembrolizumab plus Gebasaxturev

Pembrolizumab

Pembrolizumab plus MK-4830

Favezelimab plus Pembrolizumab

Pembrolizumab plus all-trans retinoic acid (ATRA)

pCR_dual: 38% vs. pCR_P: 40%

pPR_dual: 31% vs. pPR_P: 27%

RFS_dual (18 m): 95% vs. RFS_P (18 m): 73%

ORR_dual: 50% vs. ORR_P: 27%

EFS_dual (18 m): 81% vs. EFS_P (18 m): 79%

67

NCT03554083

2

Recruiting

Melanoma

Atezolizumab plus Tiragolumab

Vemurafenib plus Cobimetinib plus Atezolizumab

Cobimetinib plus Atezolizumab

-

68

NCT05116202

1/2

Recruiting

Melanoma

Atezolizumab plus Tiragolumab

RO7247669 plus Tiragolumab

Nivolumab plus Ipilimumab

RO7247669

-

69

NCT02861573

1/2

Recruiting

Metastatic Castration-Resistant Prostate Cancer

MK-7684 A

Pembrolizumab plus Olaparib

Pembrolizumab plus Docetaxel plus Prednisone

Pembrolizumab plus Enzalutamide

Pembrolizumab plus Abiraterone plus Prednisone

Pembrolizumab plus Lenvatinib

Pembrolizumab plus Carboplatin plus Etoposide

Carboplatin plus Etoposide

Belzutifan

Pembrolizumab plus Belzutifan

-

70

NCT04672356

1

Active, not recruiting

NSCLC

IBI939 plus Sintilimab

-

-

71

NCT04672369

1

Active, not recruiting

NSCLC

IBI939 plus Sintilimab

Sintilimab

ORR_dual: 66.7% (18/27) vs. ORR_P: 61.5% (8/13)

mPFS_dual: NR vs. mPFS_P: 6.0 m (HR = 0.43)

72

NCT03563716

2

Active, not recruiting

NSCLC

Atezolizumab plus Tiragolumab

Atezolizumab plus Placebo

ORRdual: 31.3% vs. ORRP: 16.2%

mPFSdual: 5.4 m vs. mPFSP: 3.6 m (HR = 0.57)

73

NCT04725188

2

Active, not recruiting

NSCLC

MK-7684 A plus chemotherapy

MK-7684 A

chemotherapy

Did not reach statistical significance for PFS and was numerically less effective than Docetaxel

74

NCT04262856

2

Active, not recruiting

NSCLC

Zimberelimab plus Domvanalimab plus Etrumadenant

Zimberelimab plus Domvanalimab

Zimberelimab

ORR_dual+O: 40% vs. ORR_dual: 41% vs. ORR_P: 27%

mPFS_dual+O: 10.9 m vs. mPFS_P: 5.4 m (HR = 0.65)

mPFS_dual: 12.0 m vs. mPFS_P: 5.4 m (HR = 0.55)

75

NCT03819465

1

Active, not recruiting

NSCLC

AZD2936

AZD2936 plus chemotherapy

Durvalumab

Durvalumab plus danvatirsen

Durvalumab plus oleclumab

MEDI5752

Durvalumab plus Investigator’s choice of chemotherapy

Durvalumab plus Investigator’s choice of chemotherapy plus danvatirsen

Durvalumab plus investigator’s choice of chemotherapy plus oleclumab

-

76

NCT04585815

2

Active, not recruiting

NSCLC

SEA-TGT plus sasanlimab plus Axitinib

Sasanlimab plus Encorafenib plus inimetinib

-

77

NCT05034055

2

Not yet recruiting

NSCLC

Atezolizumab plus Tiragolumab plus SBRT

-

-

78

NCT05798663

2

Not yet recruiting

NSCLC

Atezolizumab plus Tiragolumab

Atezolizumab

-

79

NCT05825625

2

Not yet recruiting

NSCLC

Tiragolumab plus Atezolizumab with chemotherapy

-

-

80

NCT05746481

2

Not yet recruiting

NSCLC

Tiragolumab plus Atezolizumab plus Pemetrexed plus Carboplatin

-

-

81

NCT05791097

3

Not yet recruiting

NSCLC

Ociperlimab + Tislelizumab + chemotherapy

Placebo + Pembrolizumab + chemotherapy

Placebo + Tislelizumab + chemotherapy

-

82

NCT04995523

1/2

Recruiting

NSCLC

AZD2936

-

-

83

NCT04791839

2

Recruiting

NSCLC

Zimberelimab plus Domvanalimab plus Etrumadenant

-

-

84

NCT05211895

3

Recruiting

NSCLC

Durvalumab plus Domvanalimab

Durvalumab plus Placebo

-

85

NCT04746924

3

Recruiting

NSCLC

Tislelizumab plus Ociperlimab

Pembrolizumab plus Placebo

Tislelizumab plus Placebo

-

86

NCT04294810

3

Recruiting

NSCLC

Atezolizumab plus Tiragolumab

Atezolizumab plus Placebo

-

87

NCT04958811

2

Recruiting

NSCLC

Tiragolumab plus Atezolizumab plus Bevacizumab

-

-

88

NCT04513925

3

Recruiting

NSCLC

Atezolizumab plus Tiragolumab

Durvalumab

-

89

NCT05014815

2

Recruiting

NSCLC

Ociperlimab plus Tislelizumab plus chemotherapy

Placebo plus Tislelizumab plus chemotherapy

-

90

NCT04619797

2/3

Recruiting

NSCLC

Tiragolumab plus Atezolizumab plus chemotherapy

Placebo plus Pembrolizumab plus chemotherapy

-

91

NCT05502237

3

Recruiting

NSCLC

Zimberelimab plus Domvanalimab plus chemotherapy

Pembrolizumab plus chemotherapy

Zimberelimab plus chemotherapy

-

92

NCT04738487

3

Recruiting

NSCLC

MK-7684 A (Pembrolizumab/Vibostolimab)

Pembrolizumab

-

93

NCT05298423

3

Recruiting

NSCLC

MK-7684 A (Pembrolizumab/Vibostolimab) plus chemotherapy plus radiotherapy

Durvalumab plus chemotherapy plus radiotherapy

-

94

NCT04832854

2

Recruiting

NSCLC

Tiragolumab plus Atezolizumab

Tiragolumab plus Atezolizumab plus chemotherapy

chemotherapy

-

95

NCT05226598

3

Recruiting

NSCLC

MK-7684 A plus chemotherapy

Pembrolizumab plus chemotherapy

-

96

NCT04866017

3

Recruiting

NSCLC

Ociperlimab plus Tislelizumab plus chemoradiotherapy

Tislelizumab plus chemoradiotherapy

Durvalumab plus chemoradiotherapy

-

97

NCT05102214

1/2

Recruiting

NSCLC

HLX301

-

-

98

NCT04736173

3

Recruiting

NSCLC

Zimberelimab plus Domvanalimab

Carboplatin plus paclitaxel or pemetrexed

Zimberelimab

-

99

NCT04612751

1

Recruiting

NSCLC

Datopotamab deruxtecan plus AZD2936

Datopotamab deruxtecan plus AZD2936 plus Carboplatin

Datopotamab deruxtecan plus Durvalumab

Datopotamab deruxtecan plus Durvalumab plus Carboplatin

Datopotamab deruxtecan plus MEDI5752

Datopotamab deruxtecan plus MEDI5752 plus Carboplatin

-

100

NCT05676931

2

Recruiting

NSCLC

Domvanalimab plus Zimberelimab

Domvanalimab plus Zimberelimab plus Platinum Doublet Chemotherapy

Domvanalimab plus Quemliclustat plus Zimberelimab plus Platinum Doublet Chemotherapy

Domvanalimab plus Zimberelimab plus Docetaxel

Quemliclustat plus Zimberelimab

Quemliclustat plus Zimberelimab plus Platinum Doublet Chemotherapy

Quemliclustat plus Zimberelimab plus Docetaxel

-

101

NCT05633667

2

Recruiting

NSCLC

Sacituzumab Govitecan-hziy plus Zimberelimab plus Domvanalimab

Etrumadenant plus Zimberelimab plus Domvanalimab

Etrumadenant plus Zimberelimab

Zimberelimab plus Platinum Based Chemotherapy

Etrumadenant plus Zimberelimab plus Sacituzumab Govitecan-hziy

Either Docetaxel or Sacituzumab Govitecan-hziy monotherapy

-

102

NCT05565378

2

Recruiting

NSCLC

EOS-448 plus Dostarlimab

Pembrolizumab Monotherapy

Dostarlimab Monotherapy

-

103

NCT03739710

2

Recruiting

NSCLC

EOS-448 plus Dostarlimab

EOS-448 plus Dostarlimab plus GSK6097608

feladilimab plus ipilimumab

Docetaxel

Docetaxel plus Feladilimab

-

104

NCT04165070

2

Recruiting

NSCLC

Pembrolizumab plus Vibostolimab plus Carboplatin plus Paclitaxel

Pembrolizumab plus Vibostolimab plus Carboplatin plus Pemetrexed

Pembrolizumab plus Boserolimab plus Carboplatin plus Paclitaxel

Pembrolizumab plus Boserolimab plus Carboplatin plus Pemetrexed

Pembrolizumab plus MK-4830 plus Carboplatin plus Paclitaxel

Pembrolizumab plus MK-4830 plus Carboplatin plus Pemetrexed

Pembrolizumab plus MK-0482 plus Carboplatin plus Paclitaxel

Pembrolizumab plus MK-0482 plus Carboplatin plus Pemetrexed

-

105

NCT05577702

2

Recruiting

NSCLC

Tislelizumab and Ociperlimab

Tislelizumab Monotherapy

Tislelizumab and LBL-007

-

106

NCT05681039

2

Not yet recruiting

Oral Cavity Squamous Cell Carcinoma

Tiragolumab Plus Atezolizumab

-

-

107

NCT05715216

2

Recruiting

Ovarian Cancer

Etigilimab plus Nivolumab

-

-

108

NCT05419479

1/2

Recruiting

Pancreatic Cancer

domvanalimab plus Zimberelimab plus APX005M

FOLFIRI

-

109

NCT03193190

1/2

Recruiting

Pancreatic Cancer

Atezolizumab plus Chemotherapy plus Tiragolumab

Nab-Paclitaxel and Gemcitabine

Atezolizumab plus Chemotherapy plus Selicrelumab

Atezolizumab plus Chemotherapy plus Bevacizumab

Atezolizumab plus Chemotherapy plus AB928

Atezolizumab plus Cobimetinib

Atezolizumab plus PEGPH20

Atezolizumab plus BL-8040

Atezolizumab plus RO6874281

Nab-Paclitaxel and Gemcitabine or mFOLFOX6

Atezolizumab plus Chemotherapy plus Tocilizumab

-

110

NCT05009069

2

Recruiting

Rectal Cancer

Tiragolumab plus Atezolizumab plus radiotherapy

Atezolizumab

-

111

NCT04626479

1/2

Recruiting

Renal Cell Carcinoma

MK-7684 A plus Belzutifan

Coformulation Pembrolizumab/Quavonlimab plus Lenvatinib

Coformulation Favezelimab/Pembrolizumabplus Lenvatinib

Pembrolizumab plus Belzutifan plus Lenvatinib

Pembrolizumab plus Lenvatinib

-

112

NCT05805501

2

Recruiting

Renal Cell Carcinoma

RO7247669 plus Tiragolumab plus Axitinib

RO7247669 plus Axitinib

Pembrolizumab plus Axitinib

-

113

NCT04952597

2

Active, not recruiting

SCLC

Ociperlimab plus Tislelizumab plus chemoradiotherapy

Tislelizumab plus Concurrent Chemoradiotherapy

Concurrent Chemoradiotherapy

-

114

NCT04256421

3

Active, not recruiting

SCLC

Tiragolumab plus Atezolizumab plus chemotherapy

Placebo plus Atezolizumab plus chemotherapy

mPFS_dual+C: 5.4 m vs. mPFS_P+C: 5.6 m (HR = 1.11)

mOS_dual+C: 13.6 m vs. mOS_P+C: 13.6 m (HR = 1.04)

DoR_dual+C: 4.2 m vs. DoR_P+C: 5.1 m

115

NCT04308785

2

Active, not recruiting

SCLC

Atezolizumab plus Tiragolumab

Atezolizumab plus Placebo

-

116

NCT04665856

3

Active, not recruiting

SCLC

Tiragolumab plus Atezolizumab plus chemotherapy

Placebo plus Atezolizumab plus chemotherapy

-

117

NCT05224141

3

Recruiting

SCLC

MK-7684 A plus chemotherapy

Atezolizumab plus chemotherapy

-

118

NCT04665843

2

Active, not recruiting

Squamous Cell Carcinoma of Head and Neck

Atezolizumab plus Tiragolumab

Atezolizumab plus Placebo

-

119

NCT03708224

2

Recruiting

Squamous Cell Carcinoma of Head and Neck

Atezolizumab plus Tiragolumab

Atezolizumab plus Tocilizumab

Atezolizumab Monotherapy

Atezolizumab (Adjuvant)

-

120

NCT05459129

1/2

Recruiting

Squamous Cell Carcinoma of Head and Neck

Atezolizumab plus Tiragolumab

Atezolizumab plus Tiragolumab plus Carboplatin plus Paclitaxel

-

-

121

NCT05661188

2

Not yet recruiting

Squamous Cell Carcinoma of the Anal Canal

Atezolizumab plus Tiraglolumab plus chemotherapy

-

-

122

NCT04584112

1

Active, not recruiting

Triple Negative Breast Cancer

Tiragolumab plus Atezolizumab plus chemotherapy

-

-

123

NCT05809895

2

Not yet recruiting

Triple Negative Breast Cancer

ociperlimab + tislelizumab + chemotherapy

Placebo + pembrolizumab + chemotherapy

Placebo + tislelizumab + chemotherapy

-

124

NCT05267054

1/2

Recruiting

B-cell Lymphoma

Ociperlimab plus Tislelizumab

Ociperlimab plus Rituximab

-

-

125

NCT05315713

1/2

Active, not recruiting

Hematological Malignancies

Mosunetuzumab SC plus Tiragolumab

Mosunetuzumab SC plus Tiragolumab plus Atezolizumab

-

-

126

NCT05005442

2

Recruiting

Hematological Malignancies

Pembrolizumab plus vibostolimab

-

-

127

NCT04150965

1/2

Recruiting

Multiple Myeloma

BMS-986,207

BMS-986,207 plus Pomalidimide plus Dexamethasone

Elotuzumab plus pomalidomide plus dexamethasone

Anti-LAG-3

Anti-LAG-3 plus Pomalidimide plus Dexamethasone

-

128

NCT05289492

1/2

Recruiting

Multiple Myeloma

EOS-448

EOS-448 plus Iberdomide

EOS-448 plus Iberdomide plus Dexamethasone

-

-

129

NCT05061628

1

Recruiting

Mixed Tumors:

Advanced Solid Tumor

Lymphoma

JS006 plus Toripalimab

JS006

-

-

130

NCT05390528

1/2

Recruiting

Mixed Tumors:

Advanced Solid Tumor

Lymphoma

HLX301

-

-

131

NCT04254107

1

Recruiting

Mixed Tumors:

Advanced Solid Tumor

Lymphoma

SEA-TGT

SEA-TGT plus sasanlimab

SEA-TGT plus brentuximab vedotin

-

-

132

NCT04772989

1

Recruiting

Mixed Tumors:

Advanced Solid Tumor

Lymphoma

AB308 plus Zimberelimab

-

-